Sun Pharma to buy Organon in $11.75 billion all-cash deal

Sun Pharmaceutical Industries will buy Organon & Co in an all‑cash deal, valuing ‌the U.S. ⁠drugmaker ⁠at about $11.75 billion including debt, the companies said on Sunday.

Under the definitive agreement, Sun Pharma will ⁠buy all ‌the outstanding shares of Organon ⁠for $14.00 per share in cash, the companies said in a joint statement.

The deal would give Sun Pharma full ‌ownership of Organon, which was spun off from ⁠Merck in 2021 that focuses on women's health, biosimilars and established medicines.